The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease

Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction and severe gastric ulcer. * Lymphoid malignancy. * Infectious mononucleosis caused by cytomegalovirus or Epstein-Barr virus. * Heart disease (especially if receiving cardiac glycosides). * Hemophilia. Patients with the following are excluded: * Kaposi's sarcoma or overt opportunistic infections as follows: * Candida albicans, Pneumocystis carinii, Herpes simplex, Cryptococcus neoformans, Histoplasma capsulatum, Mycobacterium avium-intracellulare, Toxoplasma gondii, Legionella, Cryptosporidium, Isospora, and Papovavirus. * Active evidence of infectious mononucleosis caused by Epstein-Barr virus (EBV) or cytomegalovirus (CMV) as determined by heterophil test (EBV) or cell culture (CMV). * History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer. * Critical illness. * Condition requiring hospitalization. * Women of childbearing age are excluded. * Hemophilia. Prior Medication: Excluded: * Steroids. * Cytotoxic immunosuppressive agents. * Antiviral medicine. Prior Treatment: Excluded: * Radiotherapy. Patients who have unexplained immunodepression and are at risk of developing AIDS. * Patients with prolonged generalized lymphadenopathy for 3 or more months (greater than 1 cm at two or more noncontiguous sites). IV drug abuse.